OBJECTIVE: The authors' goal was to determine potential hemodynamic consequences of methylphenidate on functional magnetic resonance imaging (MRI) blood-oxygen-level-dependent (BOLD) contrast. METHOD: BOLD and perfusion changes were recorded from the motor cortex of six healthy subjects while they performed flexion-extension movements of the right index finger (finger tapping) at varying rates before and after oral methylphenidate administration. RESULTS: Functional MRI signals increased monotonically with faster movement rates. Subjects' heart rates increased modestly after methylphenidate administration, but no changes in finger tapping performance or functional MRI signals were observed. CONCLUSIONS: Methylphenidate does not alter BOLD neural-hemodynamic coupling. Consequently, functional MRI can be used to map neural systems that subserve cognitive operations (e.g., attention and executive processes) in subjects taking methylphenidate.
OBJECTIVE: The authors' goal was to determine potential hemodynamic consequences of methylphenidate on functional magnetic resonance imaging (MRI) blood-oxygen-level-dependent (BOLD) contrast. METHOD: BOLD and perfusion changes were recorded from the motor cortex of six healthy subjects while they performed flexion-extension movements of the right index finger (finger tapping) at varying rates before and after oral methylphenidate administration. RESULTS: Functional MRI signals increased monotonically with faster movement rates. Subjects' heart rates increased modestly after methylphenidate administration, but no changes in finger tapping performance or functional MRI signals were observed. CONCLUSIONS:Methylphenidate does not alter BOLD neural-hemodynamic coupling. Consequently, functional MRI can be used to map neural systems that subserve cognitive operations (e.g., attention and executive processes) in subjects taking methylphenidate.
Authors: Ashley A Scott-Van Zeeland; Mirella Dapretto; Dara G Ghahremani; Russell A Poldrack; Susan Y Bookheimer Journal: Autism Res Date: 2010-04 Impact factor: 5.216
Authors: Sophia Mueller; Anna Costa; Daniel Keeser; Oliver Pogarell; Albert Berman; Ute Coates; Maximilian F Reiser; Michael Riedel; Hans-Jürgen Möller; Ulrich Ettinger; Thomas Meindl Journal: Hum Brain Mapp Date: 2014-05-23 Impact factor: 5.038
Authors: Ulrich Müller; J Suckling; F Zelaya; G Honey; H Faessel; S C R Williams; C Routledge; J Brown; T W Robbins; E T Bullmore Journal: Psychopharmacology (Berl) Date: 2005-09-14 Impact factor: 4.530
Authors: Katherine N Hewitt; Yasmene B Shah; Malcolm J W Prior; Peter G Morris; Chris P Hollis; Kevin C F Fone; Charles A Marsden Journal: Psychopharmacology (Berl) Date: 2005-04-28 Impact factor: 4.530
Authors: Chiang-Shan R Li; Peter T Morgan; David Matuskey; Osama Abdelghany; Xi Luo; Jeremy L K Chang; Bruce J Rounsaville; Yu-shin Ding; Robert T Malison Journal: Proc Natl Acad Sci U S A Date: 2010-07-26 Impact factor: 11.205
Authors: Olivia M Farr; Sheng Zhang; Sien Hu; David Matuskey; Osama Abdelghany; Robert T Malison; Chiang-Shan R Li Journal: Int J Neuropsychopharmacol Date: 2014-05-13 Impact factor: 5.176
Authors: David Matuskey; Xi Luo; Sheng Zhang; Peter T Morgan; Osama Abdelghany; Robert T Malison; Chiang-shan R Li Journal: Psychiatry Res Date: 2013-08-23 Impact factor: 3.222
Authors: Peter C T Hawkins; Fernando O Zelaya; Owen O'Daly; Stefan Holiga; Juergen Dukart; Daniel Umbricht; Mitul A Mehta Journal: Hum Brain Mapp Date: 2021-03-05 Impact factor: 5.038